Eisai R&d Management Co., Ltd.

National Cancer Center

Saori Miyano

Yasuhiro Funahashi

Akihiko Tsuruoka

Yuji Yamamoto

Kenichi Nomoto

Atsumi Yamaguchi

Takayuki Nakagawa

Tatsuhiro Shibata

Taisuke Hoshi

Tomio Nakamura

Yasuhito Arai

Michio Kanekiyo

Yukinori Minoshima

Satoshi Goda

Hajime Shimizu

Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

Biomarkers for a therapy comprising a sorafenib compound

The present application discloses a therapeutic agent for breast cancer, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Therapeutic agent for breast cancer

The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Therapeutic agent for bile duct cancer

Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Therapeutic agent for hepatocellular carcinoma

Growing community of inventors

Tsukubamirai, Japan

Saori Miyano